Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4845)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 15, 2024 (publication date) through Nov 28, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth? World J Diabetes 2024; 15(5): 818-822 [PMID: 38766425 DOI: 10.4239/wjd.v15.i5.818] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth? World J Diabetes 2024; 15(5): 818-822 [PMID: 38766425 DOI: 10.4239/wjd.v15.i5.818] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v15/i5/818.htm |
| Number | Citing Articles |
| 1 |
Filippo Biondi, Rosalinda Madonna. The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review. Journal of Clinical Medicine 2025; 14(8): 2705 doi: 10.3390/jcm14082705
|
| 2 |
Maria Ahmad, Ayesha Sikandar, Abdul Aziz, Wisam Bachar Al Sumodi, Aakash Hans, Muhammad Usman. Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials. Cureus 2025; doi: 10.7759/cureus.89514
|
| 3 |
Rachel Ranson, Philip M. Parel, Julia Kirkland, Jackson W. Durbin, Jordan C. Villa, Robert Sterling. GLP-1 agonists are protective against postoperative complications following total knee arthroplasty. The Knee 2025; 57: 77 doi: 10.1016/j.knee.2025.08.007
|
| 4 |
Nina M. Radisavljevic, Slavica S. Mutavdzin Krneta, Dragan M. Djuric. Cardiovascular Toxicity. Advances in Biochemistry in Health and Disease 2025; 33: 153 doi: 10.1007/978-3-031-90598-8_9
|
| 5 |
Antony Gonzales-Uribe, Renato Ruiz-Cortez, Nicole Collantes-Silva, Lorenzo Olivero, Raksheeth Agarwal, Sebastian Arambulo-Castillo, Alonso Garcia-Geng, Xiajie Lyu, Daniel Mendoza-Quispe, Victor Becerra-Gonzales, Hoda Butrous. Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis. Clinical Research in Cardiology 2025; doi: 10.1007/s00392-025-02710-8
|
| 6 |
Paulo César Gete Palacios, Alberto Moscona-Nissan, Renata Saucedo, Aldo Ferreira-Hermosillo. Impact on Metabolism Generated by Surgical and Pharmacological Interventions for Weight Loss in Women with Infertility. Metabolites 2025; 15(4): 260 doi: 10.3390/metabo15040260
|
| 7 |
Miguel-Angel Muñoz, Victoria Cendrós, Elena Navas, Jose-Maria Verdú-Rotellar, Joan Barrot, Josep Franch. Incidence of first hospitalization for heart failure in type 2 diabetes mellitus: A population-based cohort study in primary care. Primary Care Diabetes 2025; 19(5): 471 doi: 10.1016/j.pcd.2025.07.009
|
| 8 |
Timothy Valk, Carol McMorrow. A proposed model using glycation metrics and circulating biomarkers for the prevention of cardiovascular disease. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1624682
|
| 9 |
Nicola Riccardo Pugliese, Francesco Paneni, Domenico Tricò, Alessandra Violet Bacca, Nicolò De Biase, Hermann Dalpiaz, Alessandro Mengozzi, Agostino Virdis, Lorenzo Ghiadoni, Stefano Taddei, Reinhold Kreutz, Konstantinos Tsioufis, Stefano Masi. Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures. Cardiovascular Diabetology 2025; 24(1) doi: 10.1186/s12933-025-02778-6
|
| 10 |
Mingzhu Lv, Mengmeng Yue, Min Yang, Xiaolei Li, Kun Wu, Ting Yao, Hang Qian, Long Chen, Wenwen Wu, Xinwen Min, Handong Yang, Hao Xu, Aihua Mei, Jun Chen. An Association Between GLP-1 Receptor Expression on Regulatory T Cells and the Severity of Coronary Artery Stenosis and Inflammatory Dysregulation in Coronary Heart Disease. Reviews in Cardiovascular Medicine 2025; 26(9) doi: 10.31083/RCM39927
|
| 11 |
Simone Pasquale Crispino, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia, Francesco Grigioni. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure. Biomolecules 2025; 15(11): 1574 doi: 10.3390/biom15111574
|
| 12 |
Kazuki Nishida, Basile Chrétien, Charles Dolladille, Takumi Ebina, Branko Aleksic, Nicolas Cabé, Véronique Savey, Takeshi Onoue, Hiroshi Yatsuya. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study. Clinical Nutrition 2025; 51: 252 doi: 10.1016/j.clnu.2025.06.011
|
| 13 |
Ashkan Hashemi, Min Ji Kwak, Parag Goyal. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults. Drugs & Aging 2025; 42(2): 95 doi: 10.1007/s40266-024-01165-2
|
| 14 |
Mesk Alkhatib, Noor Almasri, Sakhr Alshwayyat, Hebah Almahariq, Bara M. Hammadeh, Zaid Taimeh, Lean Alkhatib, Anas Alshwayat, Nesreen A Saadeh, Mohammed Al-mahdi Al-kurdi. The multifaceted effects of semaglutide: exploring its broad therapeutic applications. Future Science OA 2025; 11(1) doi: 10.1080/20565623.2025.2483607
|
| 15 |
Xuan Wang, Mengmeng Qi, Lili Yang, Libo Yang, Xiaoyue Wang, Fang Zhang, Yukun Cui, Dongxin Wang, Yangang Wang, Wenshan Lv. GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1614726
|